selected scholarly activity
-
books
- Foreword 2010
-
chapters
- Quality of Life of the Treatment Process in Pediatric Oncology: An Approach to Measurement. 73-88. 2021
- Controlling health expenditures-The Canadian reality. 9-22. 2018
- Utility in Health Studies 2005
- Health States Worse than Death. 1085-1089. 1984
- A MAINTENANCE POLICY MODEL FOR ARTIFICIAL HEART PACEMAKERS. 1700-1704. 1981
- MULTI-ATTRIBUTE UTILITY INDEX FOR CHILDREN'S HEALTH. 1750-1754. 1981
- Utility in Health Studies
-
conferences
- INCORPORATING MORTALITY IN HEALTH UTILITY MEASURES. Medical decision making. E195-E196. 2020
- Health Utilities Index (Hui®): Population Reference Statistics. Value in Health. A595-A595. 2013
- PMC31 CONSTRUCTION OF PRIMARY HUI3 PERSON-MEAN UTILITY SCORING FUNCTION. Value in Health. A334-A334. 2010
- PAR15 PRELIMINARY INVESTIGATION OF THE DISCRIMINATORY CAPACITY OF MEASURES OF LOW INTENSITY SYMPTOM STATE-ATTAINMENT USING THE WOMAC PAIN SUBSCALE SCORE IN PATIENTS TREATED WITH HYLAN G-F 20 FOR KNEE OSTEOARTHRITIS. Value in Health. A28-A29. 2006
- Utility Measurement in Healthcare. PharmacoEconomics (Auckland). 1069-1078. 2006
- PAR9 A MODEL TO ESTIMATE HEALTH UTILITIES INDEX MARK 3 UTILITY SCORES FROM WOMAC INDEX SCORES IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE. Value in Health. A26-A27. 2005
- PIN26 VALIDATION OF 5-ITEM INSTRUMENT FOR ASSESSING SYMPTOM SEVERITY IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS. Value in Health. 766-766. 2004
- Examining minimal perceptible clinical improvement criteria in patients treated with hylan G-F 20 for knee ostecarthritis. Annals of the Rheumatic Diseases. 357-357. 2004
- Womac 20,50,70 response levels in patients treated with hylan G-F 20 for knee osteoarthritis. Annals of the Rheumatic Diseases. 359-359. 2004
- Predictors of osteoarthritis (OA) improvement in patients treated with hylan G-F 20 for knee OA. Osteoarthritis and Cartilage. S77-S77. 2004
- Effectiveness and safety of hylan G-F 20 compared to steroid injections in patients with knee osteoarthritis.. Arthritis and Rheumatism. S484-S484. 2003
- Evaluation of the OARSI and OMERACT-OARSI set of responder criteria in patients treated with Hylan G-F 20 for knee osteoarthritis.. Arthritis and Rheumatism. S482-S482. 2003
- The burden of illness of severe nausea and vomiting of pregnancy in the United States. American Journal of Obstetrics and Gynecology. S220-S227. 2002
- Information Barriers to the Implementation of Economic Evaluations in Japan. PharmacoEconomics (Auckland). 9-15. 2002
- The Development and Use of Quality-of-Life Measures to Evaluate Health Outcomes in Japan. PharmacoEconomics (Auckland). 17-23. 2002
- Why Has the Use of Health Economic Evaluation in Japan Lagged Behind that in Other Developed Countries?. PharmacoEconomics (Auckland). 1-7. 2002
- A randomized controlled trial evaluating effectiveness and cost-effectiveness of hylan G-F 20 in patients with knee OA. Journal of Rheumatology. 9-9. 2001
- A multilinear multi-attribute utility function for the health utilities index mark 3 (HUI3). Medical decision making. 490-490. 1998
- Canada's new guidelines for the economic evaluation of pharmaceuticals.. Medical Care. DS77-DS86. 1996
- A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A RHEUMATOLOGY DAY HOSPITAL PROGRAM. Arthritis and Rheumatism. 1371-1371. 1995
- An interview on utility measurement. Interview by Bernie O'Brien.. Journal of Rheumatology. 1200-1202. 1995
- A COMPREHENSIVE ASSESSMENT OF THE HEALTH STATUS OF EXTREMELY LOW BIRTHWEIGHT CHILDREN (< 1000G UW) AND CONTROLS AT 8 YEARS OF AGE. Pediatric Research. 264-264. 1994
- HEALTH-RELATED QUALITY-OF-LIFE OF EXTREMELY LOW-BIRTH-WEIGHT CHILDREN AND CONTROLS AT AGE 8 YEARS. Quality of Life Research. 92-92. 1994
- MCMASTER HEALTH UTILITIES INDEX OF HEALTH-RELATED QUALITY-OF-LIFE. Quality of Life Research. 76-77. 1994
- MODELING THE POPULATION HEALTH IMPACT OF MUSCULOSKELETAL DISEASES - EXAMPLE OF FEMALE ARTHRITIS. American Journal of Epidemiology. 787-787. 1991
- Design issues in the measurement of quality of life in a trial of two prenatal diagnostic technologies: Genetic amniocentesis and chorionic villi sampling. Contemporary Clinical Trials. 267-268. 1990
- A COMPARISON OF COST - BARIUM MEAL VERSUS ENDOSCOPY IN THE INVESTIGATION OF EPIGASTRIC PAIN. Clinical Research. A269-A269. 1985
- QUALITY OF LIFE (QL) IN END STAGE RENAL-DISEASE (ESRD) - RELIABILITY, VALIDITY AND USE OF THE TIME TRADE-OFF (TTO) METHOD. Clinical Research. A246-A246. 1985
- QUALITY OF LIFE (QL) IN END STAGE RENAL-DISEASE - RELIABILITY + VALIDITY OF THE TIME TRADE OFF METHOD (TTO). Clinical and Investigative Medicine. A86-A86. 1985
- 'COOKBOOK' COST ANALYSIS PROCEDURE FOR MEDICAL INFORMATION SYSTEMS.. Proceedings Annual Symposium on Computer Applications in Medical Care. 621-624. 1983
- COST-EFFECTIVENESS ANALYSIS (CEA) COMPARING CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS (CAPD) TO HOSPITAL HEMODIALYSIS (HD). Medical decision making. 355-355. 1983
- 37 COST EFFECTIVENESS OF NEONATAL INTENSIVE CARE (NIC). Pediatric Research. 446-446. 1981
- 473 PRENATAL SELECTION BIAS IN THE EVALUATION OF NEONATAL INTENSIVE CARE (NIC). Pediatric Research. 519-519. 1981
-
journal articles
- Response letter to the editor. American Journal of Managed Care. 20:921-921. 2020
- Incorporating Mortality in Health Utility Measures. Medical decision making. 40:862-872. 2020
- Commentary. In Praise of Studies That Use More Than One Generic Preference-Based Measure. International Journal of Technology Assessment in Health Care. 35:257-262. 2019
- What were they thinking when providing preference measurements for generic health states? The evidence for HUI3. Health and Quality of Life Outcomes. 16:166. 2018
- Erratum. Value in Health. 13:1065-1065. 2010
- BLISS index using WOMAC index detects between-group differences at low-intensity symptom states in osteoarthritis. Journal of Clinical Epidemiology. 63:566-574. 2010
- QALYs: The Basics. Value in Health. 12:S5-S9. 2009
- Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?. European Journal of Preventive Cardiology (EJPC). 15:608-615. 2008
- Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip. Value in Health. 11:470-477. 2008
- Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada. PharmacoEconomics (Auckland). 26:477-495. 2008
- A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee.. Journal of Rheumatology. 34:534-542. 2007
- BLISS index for analyzing knee osteoarthritis trials data. Journal of Clinical Epidemiology. 60:124-132. 2007
- Economic evaluation of control led-released oxycodone vs oxycodone-. acetaminophen for osteoarthritis pain of the hip or knee.. American Journal of Managed Care. 12:412-+. 2006
- Measuring quality of life: The development and initial validation of the Patient-Reported Erectile Function Assessment instrument. International Journal of Technology Assessment in Health Care. 22:372-378. 2006
- Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee.. American Journal of Managed Care. 12:205-214. 2006
- The Erectile Function Visual Analog Scale (EF-VAS): a disease-specific utility instrument for the assessment of erectile function.. Canadian Journal of Urology. 13:3016-3025. 2006
- Letter to the Editor: Reply to the letter by Max I. Hamburger. Osteoarthritis and Cartilage. 13:1037-1038. 2005
- PAR3 PRODUCTIVITY BENEFITS FROM CONTROLLED-RELEASE VS SHORT ACTING OPIOIDS FOR TREATMENT OF PERSISTENT MODERATE TO SEVERE OSTEOARTHRITIS (OA) PAIN OF THE HIP/KNEE. Value in Health. 8:A24-A25. 2005
- Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Annals of the Rheumatic Diseases. 64:881-885. 2005
- MS3 ECONOMIC EVALUATION OF CONTROLLED-RELEASE OXYCODONE (OXYCONTIN®TABLETS) (CRO) VERSUS OXYCODONE/ACETAMINOPHEN (PERCOCET®) (OXY/APAP) FOR OSTEOARTHRITIS PAIN OF THE HIP OR KNEE. Value in Health. 8:241-241. 2005
- Effectiveness and safety of repeat courses of hylan G-F 20 in patients with knee osteoarthritis. Osteoarthritis and Cartilage. 13:111-119. 2005
- The effectiveness of hylan G-F 20 in patients with knee osteoarthritis: an application of two sets of response criteria developed by the OARSI and one set developed by OMERACT–OARSI. Osteoarthritis and Cartilage. 13:104-110. 2005
- Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology. 43:712-718. 2004
- Development and initial validation of a new preference-based disease-specific health-related quality of life instrument for erectile function. Quality of Life Research. 13:349-359. 2004
- Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.. Wound Management and Prevention. 49:76-84. 2003
- Switching Therapy in Health Economics Trials: Confronting the Confusion. Medical decision making. 23:335-340. 2003
- PMDI9: COMMUNITY OR PATIENT PREFERENCES FOR COST-UTILITY ANALYSES: DOES IT MATTER?. Value in Health. 6:298-298. 2003
- Response to Dr C. Daniel Mullins’ letter [re: Osteoarthritis and Cartilage, 2002; 10:518–27]. Osteoarthritis and Cartilage. 11:379-381. 2003
- Response to Torrance et al. [Osteoarthritis and Cartilage 2002; 10:518–27]. Osteoarthritis and Cartilage. 11:377-378. 2003
- The Health Utilities Index (HUI): concepts, measurement properties and applications.. Health and Quality of Life Outcomes. 1:54-54. 2003
- Willingness to Pay for What? A Note on Alternative Definitions of Health Care Program Benefits for Contingent Valuation Studies. Medical decision making. 22:493-497. 2002
- PWM5 PRELIMINARY VALIDATION OF A NEW DISEASE-SPECIFIC UTILITY MEASURE FOR ERECTILE DYSFUNCTION. Value in Health. 5:588-588. 2002
- A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis and Cartilage. 10:506-517. 2002
- A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis and Cartilage. 10:518-527. 2002
- Health utility estimation. Expert Review of Pharmacoeconomics and Outcomes Research. 2:99-108. 2002
- Health-Related Quality-of-Life Assessment of Prenatal Diagnosis: Chorionic Villi Sampling and Amniocentesis. Genetic Testing and Molecular Biomarkers. 6:39-46. 2002
- Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 System. Medical Care. 40:113-128. 2002
- How robust is the Health Utilities Index Mark 2 utility function?. Medical decision making. 22:350-358. 2002
- Looking back and looking forward: viewed through the eyes of George Torrance.. Medical decision making. 22:178-181. 2002
- POD7: THE EF-VAS: A PREFERENCE-BASED SELFADMINISTRATION INSTRUMENT FOR ASSESSING THE IMPACT OF ERECTILE DYSFUNCTION (ED) AND ED TREATMENT. Value in Health. 4:468-469. 2001
- Cost-effectiveness of Apligraf in the treatment of venous leg ulcers.. Wound Management and Prevention. 47:36-46. 2001
- The Health Utilities Index (HUI®) system for assessing health-related quality of life in clinical studies. Annals of Medicine. 33:375-384. 2001
- Visual analog scales: do they have a role in the measurement of preferences for health states?. Medical decision making. 21:329-334. 2001
- What should be reported in a methods section on utility assessment?. Medical decision making. 21:200-207. 2001
- Cost-Utility Analysis in Depression: The McSad Utility Measure for Depression Health States. Psychiatric Services. 51:1171-1176. 2000
- Cost and health related quality of life consequences of multiple sclerosis.. Multiple Sclerosis. 6:91-98. 2000
- Development and testing of a utility measure for major, unipolar depression (McSad).. Quality of Life Research. 9:109-120. 2000
- WMM2: ECONOMIC EVALUATION OF PROSPECTIVE MULTINATIONAL CLINICAL TRIALS: A MODELING APPROACH. Value in Health. 2:229-229. 1999
- Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Climacteric. 2:237-237. 1999
- Economic Evaluation of Ciprofloxacin Compared with Usual Antibacterial Care for the Treatment of Acute Exacerbations of Chronic Bronchitis in Patients Followed for 1 Year. PharmacoEconomics (Auckland). 16:499-520. 1999
- The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. PharmacoEconomics (Auckland). 15:459-468. 1999
- MGA5 Health Utilities Index: Further Evidence of Responsiveness. Value in Health. 1:41-41. 1998
- MGA6 Survey Strategies in the Revision of the Guidelines for Economic Evaluation: Canada. Value in Health. 1:41-42. 1998
- UT2 Practical Applications of the Health Utilities Index. Value in Health. 1:93-93. 1998
- Product review. American Journal of Preventive Medicine. 14:243-243. 1998
- Assessing the Value of a New Pharmaceutical. Medical Care. 36:370-384. 1998
- Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis. PharmacoEconomics (Auckland). 14:559-573. 1998
- Medical Necessity, Benefit and Resource Allocation in Health Care. Journal of Health Services Research and Policy. 2:223-230. 1997
- Health state utilities in knee replacement surgery: the development and evaluation of McKnee.. Journal of Rheumatology. 24:1796-1805. 1997
- Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Economics. 6:505-510. 1997
- The Negative Side of Cost-effectiveness Analysis-Reply. Journal of the American Medical Association (JAMA). 277:1933-1933. 1997
- The negative side of cost-effectiveness analysis.. Journal of the American Medical Association (JAMA). 277:1931-1932. 1997
- Preferences for health outcomes and cost-utility analysis.. American Journal of Managed Care. 3 Suppl:S8-20. 1997
- Reporting Cost-effectiveness Analyses With Confidence-Reply. Journal of the American Medical Association (JAMA). 277:375-375. 1997
- Reporting cost-effectiveness analyses with confidence.. Journal of the American Medical Association (JAMA). 277:375. 1997
- Guidelines for Pharmacoeconomic Studies. PharmacoEconomics (Auckland). 11:159-168. 1997
- P-14.. Menopause. 4:255-255. 1997
- Multiattribute Utility Function for a Comprehensive Health Status Classification System. Medical Care. 34:702-722. 1996
- Canadian Guidelines for Economic Evaluation of Pharmaceuticals. PharmacoEconomics (Auckland). 9:535-559. 1996
- Utility-based measures of health-related quality of life in depression. European Neuropsychopharmacology. 6:128-128. 1996
- The monetary costs of childhood cancer to the families of patients. International Journal of Oncology. 8:933-940. 1996
- Current Experience with Guidelines for Economic Evaluation in Canada. Therapeutic Innovation and Regulatory Science. 30:507-511. 1996
- Assessing the Economic Value of a New Antidepressant. PharmacoEconomics (Auckland). 8:34-45. 1995
- Multi-Attribute Health Status Classification Systems. PharmacoEconomics (Auckland). 7:490-502. 1995
- Multi-Attribute Preference Functions. PharmacoEconomics (Auckland). 7:503-520. 1995
- Reliability of the Health Utilities Index—Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Quality of Life Research. 4:249-257. 1995
- Promoting cost effective prescribing. The BMJ. 310:955-956. 1995
- Cost-effectiveness league tables: think of the fans. Health Policy. 31:231-238. 1995
- A PREFERENCE-BASED APPROACH TO HEALTH-RELATED QUALITY-OF-LIFE FOR CHILDREN WITH CANCER. International Journal of Pediatric Hematology/Oncology. 2:305-315. 1995
- Comparison of the health-related quality of life of extremely low birth weight children and a reference group of children at age eight years. Journal of Pediatrics. 125:418-425. 1994
- Comprehensive assessment of the health status of extremely low birth weight children at eight years of age: Comparison with a reference group. Journal of Pediatrics. 125:411-417. 1994
- A MULTIATTRIBUTE APPROACH TO HEALTH-STATUS MEASUREMENT AND CLINICAL MANAGEMENT ILLUSTRATED BY AN APPLICATION TO BRAIN-TUMORS IN CHILDHOOD. International Journal of Oncology. 4:639-648. 1994
- The comprehensive assessment of health status in survivors of childhood cancer: application to high-risk acute lymphoblastic leukaemia.. Rehabilitation Oncology. 12:22-22. 1994
- A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis.. Journal of Rheumatology. 20:2095-2103. 1993
- An assessment of global health status in survivors of acute lymphoblastic leukemia in childhood.. Journal of Pediatric Hematology/Oncology. 15:284-290. 1993
- Cost-effectiveness league tables: More harm than good?. Social Science and Medicine. 37:33-40. 1993
- Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. American Journal of Cardiology. 72:154-161. 1993
- Modelling the population health impact of musculoskeletal diseases: arthritis.. Journal of Rheumatology. 20:1037-1047. 1993
- The population health impact of arthritis. POHEM Workshop Group.. Journal of Rheumatology. 20:1048-1051. 1993
- The comprehensive assessment of health status in survivors of childhood cancer: application to high-risk acute lymphoblastic leukaemia. British Journal of Cancer. 67:1047-1052. 1993
- Some guidelines on the use of cost effectiveness league tables.. The BMJ. 306:570-572. 1993
- Physical disability among Canadians reporting musculoskeletal diseases.. Journal of Rheumatology. 19:1020-1030. 1992
- A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer.. Journal of Clinical Oncology. 10:923-928. 1992
- ECONOMIC EVALUATION OF CARDIAC REHABILITATION. Medicine & Science in Sports & Exercise. 24:S2-S2. 1992
- Effects on Quality of Life With Comprehensive Rehabilitation After Acute Myocardial Infarction. Journal of Cardiopulmonary Rehabilitation and Prevention. 12:63-63. 1992
- Methodologic challenges in the development of utility measures of health-related quality of life in rheumatoid arthritis. Contemporary Clinical Trials. 12:S118-S128. 1991
- Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. American Journal of Cardiology. 67:1084-1089. 1991
- A multi-attribute utility function for the assessment of health-related quality of life in survivors of childhood cancer. Journal of Pediatric Hematology/Oncology. 13:106-106. 1991
- Utilities and Quality-Adjusted Life Years. International Journal of Technology Assessment in Health Care. 5:559-575. 1989
- Controlling Health Expenditures — the Canadian Reality. New England Journal of Medicine. 320:571-577. 1989
- Incorporating Utility-Based Quality-of-Life Assessment Measures in Clinical Trials. Medical Care. 27:S190-S204. 1989
- Nuclear Safety in Ontario: A Critical Review of Quantitative Analyses. Risk Analysis. 9:43-54. 1989
- Health Care Technology: Effectiveness, Efficiency and Public Policy. Canadian Public Policy/ Analyse de Politiques. 14:226-226. 1988
- Measuring the wellbeing of family caregivers using the time trade-off technique. Journal of Clinical Epidemiology. 41:475-482. 1988
- Measurement of quality of life in end-stage renal disease: the time trade-off approach.. Clinical and Investigative Medicine. 10:14-20. 1987
- Utility approach to measuring health-related quality of life. Journal of Clinical Epidemiology. 40:593-600. 1987
- Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. American Journal of Medicine. 81:565-578. 1986
- Measurement of health state utilities for economic appraisal. Journal of Health Economics. 5:1-30. 1986
- CHORIONIC VILLUS SAMPLING. The Lancet. 325:1269-1270. 1985
- A Cost-Effectiveness Analysis of Continuous Ambulatory Peritoneal Dialysis and Hospital Hemodialysis. Medical decision making. 4:489-500. 1984
- Developing Multiattribute Health Indexes. Medical Care. 22:1045-1057. 1984
- Costt-Effectiveness of Antepartum Prevention of Rh Immunization. Clinics in Perinatology. 11:267-281. 1984
- Clinical trial of chorion biopsy.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 130:1109. 1984
- Risk Attitude and Time Preference in Health. Management science. 30:440-451. 1984
- Quality of Life in End-Stage Renal Disease. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 4:20-23. 1984
- Intensive Care of Low-Birth-Weight Infants. New England Journal of Medicine. 309:1058-1060. 1983
- Economic Evaluation of Neonatal Intensive Care of Very-Low-Birth-Weight Infants. New England Journal of Medicine. 308:1330-1337. 1983
- INTENSIVE-CARE OF LOW-BIRTH-WEIGHT INFANTS - REPLY. New England Journal of Medicine. 309:1060-1060. 1983
- Application of Multi-Attribute Utility Theory to Measure Social Preferences for Health States. Operations Research. 30:1043-1069. 1982
- Mortality and Morbidity of 500- to 1,499-Gram Birth Weight Infants Live-born to Residents of a Defined Geographic Region Before and After Neonatal Intensive Care. Pediatrics. 69:613-620. 1982
- Economic evaluation of neonatal intensive care. Critical Care Medicine. 10:69-69. 1982
- Preferences for health states: a review of measurement methods.. Mead Johnson Symposium on Perinatal and Developmental Medicine. 37-45. 1982
- EVALUATING NEONATAL INTENSIVE CARE. The Lancet. 318:1052-1052. 1981
- Evaluation of Neonatal-Intensive-Care Programs. New England Journal of Medicine. 305:489-494. 1981
- Cost-benefit analysis versus cost-effectiveness analysis for the evaluation of long-term care programs.. Health Services Research (HSR). 16:474-476. 1981
- EVALUATING NEONATAL INTENSIVE-CARE. The Lancet. 2:1052-1052. 1981
- Computer-assisted medicine: economics of computing (part 2).. CANADIAN MEDICAL ASSOCIATION JOURNAL. 123:565-572. 1980
- Computer-assisted medicine: economics of computing (part 1).. CANADIAN MEDICAL ASSOCIATION JOURNAL. 123:322-324. 1980
- DECISIONS WITH MULTIPLE OBJECTIVES - PREFERENCES AND VALUE TRADEOFFS - KEENEY,RL, RAIFFA,H. Health Services Research (HSR). 13:328-329. 1978
- The utility of different health states as perceived by the general public. Journal of Clinical Epidemiology. 31:697-704. 1978
- Health Status Index Models: A Unified Mathematical View. Management science. 22:990-1001. 1976
- Social preferences for health states: An empirical evaluation of three measurement techniques. Socio-Economic Planning Sciences. 10:129-136. 1976
- Toward a utility theory foundation for health status index models.. Health Services Research (HSR). 11:349-369. 1976
- A comment on "Alternative estimations of population health status".. Inquiry (United States). 12:70-71. 1975
- INITIAL SOLUTION FOR THE DUAL SIMPLEX ALGORITHM ‐ A TUTORIAL NOTE. Decision Sciences. 5:422-424. 1974
- Health index and utility models: some thorny issues.. Health Services Research (HSR). 8:12-14. 1973
- A generalized cost effectiveness model for the evaluation of health programs. Abstracts of Hospital Management Studies. 9:330-7387. 1972
- A utility maximization model for evaluation of health care programs.. Health Services Research (HSR). 7:118-133. 1972